Risks of using psilocybin in treatment of treatment-resistant depression
Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek, Jan Karczmarz, Aleksandra Paprocka, Marika Gutowska, Agnieszka Kosińska, Urszula Świrk, Wiktoria Belcarz, Karolina Kalinowska
Journal of Education, Health and Sport March 7, 2025 DOI: 10.12775/JEHS.2025.79.58319 via DOAJ
Summary
AI-generated from the abstractAs depression rates rise globally, psilocybin shows promise as a treatment for treatment-resistant depression, but its safe clinical use requires clear safety parameters. This paper reviews risks associated with psilocybin therapy, drawing on a literature search of PubMed and Google Scholar for studies on challenges and risks in treating treatment-resistant depression. It aims to help understand these risks as a basis for safety-focused treatment protocols.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Treatment resistant depression Safety Psychedelic assisted therapy Adverse effects Psilocybin therapy |
| Key finding | Establishing robust safety parameters for psilocybin administration is essential for its safe integration into clinical practice for treatment-resistant depression. |
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper focuses on addressing the risks associated with psilocybin therapy. We believe this paper can help understand risks as a platform for safety based treatment. Material and Methods A comprehensive literature search was conducted using the PubMed and Google Scholar databases, supplemented by references cited in the initially identified articles. The search focused on studies and reviews addressing the challenges and risks associated with psilocybin use in the treatment of treatment-resistant depression (TRD).